MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New 'adjuvant' could hold future of vaccine

Back to research news Blogs list Cancer blog  


Subscribe To Research News RSS Feed  RSS content feed What is RSS feed?

New 'adjuvant' could hold future of vaccine




Researchers at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle a number of diseases more effectively.

Adjuvants are substances that are not immunogenic themselves, but increase the immune response when used in combination with a vaccine.

However, due to concerns about safety and toxicity, there's only a single vaccine adjuvant aluminum hydroxide, or alum that has been approved for human use in the United States. It's found in such common vaccines as hepatitis B and tetanus. But even though widely used, alum is comparatively weak and will only work with certain diseases.



New 'adjuvant' could hold future of vaccine

The new adjuvant is based on nanoparticles prepared with lecithin, a common food product. In animal models, it helped protein antigens to induce an immune response more than six times stronger than when alum was used. Scientists also showed that the lecithin nanoparticles were able to help induce a reasonable antibody response after only one shot, whereas it took at least two shots for the alum adjuvant to work.

Based on their studies, scientists believe the lecithin nanoparticles have wide potential applications and possibly a good safety profile. Their findings were just reported in the Journal of Controlled Release, a professional journal in the field of pharmaceutics, in work supported by the National Institute of Allergy and Infectious Diseases.

"In a number of cases, to make progress with vaccine development we need new adjuvants," said Zhengrong Cui, an assistant professor of pharmaceutics at OSU and corresponding author on the newly released study. "The material has to be safe, and lecithin is a common food product that's already widely used in pharmaceuticals. This new form of using lecithin nanoparticles as an adjuvant is promising and could become very important".

Vaccine development has always been difficult and at times controversial, Cui said, because of concerns about adverse effects when giving vaccines to healthy people.

Because of that, the U.S. Food and Drug Administration has been conservative about approving new vaccine adjuvants, he said. But even the safety issue is complex to help avoid risk, new vaccines are based on purified compounds from microbes, but these provoke a very weak immune response and often need an adjuvant to boost them. Vaccines could be made based on dead or live attenuated microbes, but that would have a higher level of risk. The ultimate solution is new and improved adjuvants that help address both concerns about safety and efficacy.

Another problem, he said, is that the alum adjuvant that is common in some U.S. vaccines has very limited value in the development of a number of potential vaccines against viruses or tumors.

By contrast, the lecithin-based nanoparticle adjuvant is more effective. The extraordinarily small particles move easily to the lymphatic system that plays a key role in development of immune response, and they physically "look like" a pathogen to the immune system, which quickly gears up to fight them.

"Our early studies with laboratory animals seem to suggest that a vaccine based on the lecithin nanoparticle adjuvant would not only be more effective, but be tolerated by the body more readily than one using alum," Cui said. "Lecithin is very non-toxic, it's one of a number of compounds 'generally recognized as safe' by the FDA, and at the injection site we saw none of the nodules and tissue hardening you sometimes see with vaccines that use alum".

If the new adjuvant is ultimately shown to be safe and is approved following clinical trials, Cui said, it could become the basis for a revolution in the production of vaccines and serve as a universal carrier.


Posted by: Scott    Source




Did you know?
Researchers at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle a number of diseases more effectively. Adjuvants are substances that are not immunogenic themselves, but increase the immune response when used in combination with a vaccine.

Medicineworld.org: New 'adjuvant' could hold future of vaccine

Acute bacterial meningitis| Alzheimer's disease| Carpal tunnel syndrome| Cerebral aneurysms| Cerebral palsy| Chronic fatigue syndrome| Cluster headache| Dementia| Epilepsy seizure disorders| Febrile seizures| Guillain barre syndrome| Head injury| Hydrocephalus| Neurology| Insomnia| Low backache| Mental retardation| Migraine headaches| Multiple sclerosis| Myasthenia gravis| Neurological manifestations of aids| Parkinsonism parkinson's disease| Personality disorders| Sleep disorders insomnia| Syncope| Trigeminal neuralgia| Vertigo|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.